Company leveraging space-based crystallization technology
Serendipity Space, a pioneering space-tech company developing microgravity-based pharmaceutical manufacturing solutions, has raised its pre-seed round from Bengaluru’s Campus Fund for accelerating the company’s mission to transform drug development by leveraging space-based crystallization technology through its proprietary satellite platform and autonomous pharmaceutical crystallization module called ‘Alchemy’.
Co-founded by Antariksh Parichha (CEO) – M.S. Applied Physics from Technical University of Munich, Germany (2024), Jivitesh Debata (CTO) – M.S. Computer Science from Rochester Institute of Technology, USA (2023), and Dr. Monica Ekal (Chief of Space Systems) – Ph.D. in Space Robotics from Instituto Superior Tecnico, Portugal (2023) with extensive experience as a research scientist at German Aerospace Center and visiting scholar at NASA, Serendipity Space addresses one of the pharmaceutical industry’s biggest bottlenecks – the inability to produce high-quality protein and drug crystals on Earth due to gravity-induced defects https://www.bseindia.com/.
The team combines deep space systems engineering expertise with pharmaceutical development experience and Antariksh’s personal drive inspired by witnessing how microgravity-produced drugs like Keytruda transformed cancer treatment.
“Serendipity Space represents the convergence of two critical frontiers – space technology and pharmaceutical innovation,” said Richa Bajpai, Founder & CEO of Campus Fund https://www.nseindia.com/.
“We’re backing a team that’s not just pushing the boundaries of what’s possible in space manufacturing, but solving real problems in drug development that could accelerate life-saving treatments to market,” Bajpai said on 4 Jul.
Since inception, the company has built and tested multiple functional pharmaceutical modules, including two crystallization modules and one formulation module. Their ground-based validation of the autonomous pharmaceutical module with proteins and small molecules has demonstrated laboratory-grade crystallization quality.
Space-based pharmaceutical production can yield an average net present value (NPV) of US$1.2 billion per novel drug for a pharmaceutical company and the broader in-space manufacturing market is projected to surpass US$10 billion by 2030, driven by the unique advantages provided by the microgravity environment https://www.bengalurutechsummit.com/.
In space, the absence of sedimentation, buoyancy, and convection currents enables the production of larger, more uniform protein and drug crystals with enhanced stability and bioavailability – critical factors that can reduce drug development timelines that usually takes 12-15 years.
“Our vision is to make space the new frontier for drug discovery and pharmaceutical manufacturing,” said Antariksh Parichha, Co-founder and CEO. “With Campus Fund’s backing, we’re not just building satellites – we’re creating the infrastructure that will enable the next generation of breakthrough medicines. Our reusable satellites with re-entry capability will make space-based manufacturing commercially viable https://www.meity.gov.in/ .”
With the funding, Serendipity Space plans to execute technical demonstrations that shall validate the core subsystems required to deploy this technology as an end-to-end service for pharmaceutical companies. Serendipity Space joins Campus Fund’s growing portfolio of deep-tech ventures reimagining India’s position in cutting-edge industries, from space technology to advanced manufacturing, driven by student entrepreneurs building the future of innovation. Fiinews.com
